Abstract 420P
Background
Cytoreductive surgery (CRS) is a major surgery which consist of extensive tumor debulking, peritonectomy, and multiple visceral resections. Hyperthermic intraperitoneal chemotherapy (HIPEC) is a technique in which chemotherapy is delivered in a heated solution perfused throughout the peritoneal space. In centers performing CRS-HIPEC, a significant survival benefit were observed; However, the rate of post-operative complications remains high. Acute kidney injury is a post-operative complication associated with increased morbidity and mortality and may cause delay in adjuvant chemotherapy or worse, may render the patient ineligible to receive systemic chemotherapy.
Methods
This was a retrospective cohort study, data were collected among adult patients with peritoneal carcinomatosis from colorectal, appendiceal, gastric, gynecologic cancers, and primary peritoneal mesothelioma who underwent CRS-HIPEC between Jan. 2012 and Dec. 2021 at St. Luke’s Medical Center. Data were obtained retrospectively through review of electronic medical records.
Results
A total of 162 patients who met the inclusion criteria were included in the study. Most of the patients were above 60 years old (62; 38%), females (134; 83%), had normal BMI (90; 56%), with ECOG PS 1 (160; 99%) and without comorbidities (84; 52%). Most had gynecologic malignancy (101; 63%) with high tumor grade (92; 58%) and were given with intraperitoneal cisplatin (16l 68%). Elderly patients (OR 2.70 [95% CI 0.88-8.29]; p .043 < .05); with comorbidities (OR 6.52 [95% CI 3.2-13.2]; p .001 < .05); and was given intraperitoneal Cisplatin (OR 3.99 [95% CI 1.99-8.03]; p .001 < 05) were all found to be at a higher risk for developing AKI after CRS-HIPEC.
Conclusions
The investigation noted that the elderly patients with comorbidities were found to have the highest risk of developing post-operative AKI. The most common malignancy was gynecologic cancers with high tumor grade. Cisplatin was the most common intraperitoneal chemotherapy administered and was associated with higher risk of developing acute kidney injury compared to other chemotherapy agents.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
409P - Tertiary lymphoid structures are scarce but associated with BCR clonal expansion, B cell activity and checkpoint inhibitor response in advanced osteosarcoma
Presenter: Qiyuan Bao
Session: Poster viewing 06
410P - The incidence and risk factors of kidney injury in patients receiving immune checkpoint inhibitors: A retrospective observational cohort study
Presenter: Thanawat Suksomboon
Session: Poster viewing 06
411P - Cost-effective analysis of the various cancer screening methods in the community: Pooled analysis of camps of 5 years from 2017-to 2022
Presenter: Suresh Attili
Session: Poster viewing 06
412P - Substance-P in the blood is related with the efficacy of aprepitant for targeted drug-induced refractory pruritus in Chinese malignancy population
Presenter: Fang Gao
Session: Poster viewing 06
413P - Association of concomitant medications on survival outcomes in cancer patients treated with immune checkpoint inhibitors: Analysis of health insurance review and assessment database
Presenter: Soojung Hong
Session: Poster viewing 06
414P - Lessons learnt from clinico-genomic profiling of families with Li Fraumeni Syndrome: The largest case series from the Indian setting
Presenter: Ghazal Tansir
Session: Poster viewing 06
415P - Small cell lung cancer: Epidemiological patterns and mutational profile in the United States
Presenter: Abdallah Allam
Session: Poster viewing 06
416P - Survival outcomes predicted by irAEs on 18F-FDG-PET in response to PD-1 antibody therapy in metastatic melanoma
Presenter: Sarah Lewis
Session: Poster viewing 06
417P - The activity and safety of anlotinib for patients with recurrent malignant glioma: A single-center, retrospective study
Presenter: Xudong Sun
Session: Poster viewing 06
418P - Mutational landscape of non-small cell lung cancer in the United States
Presenter: Mostafa Elsayed
Session: Poster viewing 06